MiMARK key facts
as of Oct 2026- Operator of a biotech platform designed to reshape gynecological diagnostics through fluid-based testing.
- MiMARK is valued at approximately $32.9M as of Oct 2026 (last reported valuation).
- It has raised $8.8M.
- Notable investors include European Innovation Council, Inveready Asset Management, Clave (Pamplona), PharmStars, CDTI Innvierte — 14 tracked in total.
- Status: Privately Held (backing).
MiMARK's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch MiMARK: the Monday email on marks, rounds and moves
MiMARK funding rounds
No funding rounds for MiMARK are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs MiMARK
14+MiMARK valuation
MiMARK's last reported valuation was $32.9 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
MiMARK investors
14 investors are on record for MiMARK, including European Innovation Council, Inveready Asset Management, Clave (Pamplona) and PharmStars.
About MiMARK
Operator of a biotech platform designed to reshape gynecological diagnostics through fluid-based testing. The company's platform utilizes gynecological fluid analysis as an approach to liquid biopsy, developing immunoassay-based diagnostics for conditions such as endometrial cancer, biomarker quantification for accuracy, reducing invasiveness, and supporting clinical decision-making, enabling healthcare providers to improve early detection, optimize patient outcomes, and women's health through innovative screening methods.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2021
- Employees
- 30
- Website
- mimark.es/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.